Association of polymorphisms in promoter region of TNF-alpha-238 and-308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy

The hypothesis of the study was that polymorphisms in promoter regions-238 and-308 of TNF-alpha could be associated with different clinical outcomes in inflammatory bowel diseases (IBD) and immune-mediated rheumatic diseases (IMRD). The aim was to examine the possible association of both polymorphisms with concentration of C-reactive protein (CRP) and fecal calprotectin (fCAL), onset of the remission and development of the ADA in patients on therapy with anti-TNF inhibitors. The prospective study was done in patients with IBD and IMRD on infliximab (IFX) or adalimumab (ADM). Patients were genotyped for TNF-alpha-238 and -308 polymorphisms. The concentration of CRP, fCAL, IFX or ADM and antibodies to drugs were measured according to manufacturer's instructions and followed-up for 6 or 12 months. Out of all patients (N = 112), number of patients in remission did not differ according to genotypes (for IBD patients P = 0.509 vs 0.223; for IMRD patients P = 0.541 vs 0.132 for TNF-alpha-238 and-308, respectively). Initial CRP concentration was higher in IBD patients with TNF-alpha-308 GG than GA/AA genotypes in patients who failed to achieve remission [11.8 (4.4-39.6) vs 3.1 (1.5-6.5), P = 0.033]. In IBD patients with remission, fCAL concentration after at least 6 months of therapy was higher in TNF-alpha-308 GG than in GA genotype [52 (25-552) vs 20 (20-20) mu g/g, P = 0.041]. Our results showed the association of TNF-alpha-308 GG genotype with a higher concentration of CRP and fecal calprotectin in patients with inflammatory bowel diseases on IFX or ADM therapy. Clinical remission and development of antibodies to anti-TNF drugs were not associated with TNF-alpha-238 and-308 polymorphisms.